Mirum Pharmaceuticals Announces Pricing of Public Offering
January 08 2020 - 7:15PM
Business Wire
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical
company focused on the development and commercialization of novel
therapies for debilitating liver diseases, today announced the
pricing of its public offering of 2,400,000 shares of its common
stock at a price to the public of $20.00 per share. The gross
proceeds to Mirum from the offering, before deducting underwriting
discounts and commissions and estimated offering expenses, are
expected to be $48.0 million.
In addition, Mirum has granted the underwriters a 30-day option
to purchase up to an additional 360,000 shares of common stock at
the public offering price less underwriting discounts and
commissions. The offering is expected to close on January 13, 2020,
subject to satisfaction of customary closing conditions.
Citigroup, Evercore ISI and Guggenheim Securities are acting as
joint book-running managers for the offering. Raymond James is
acting as lead manager. Roth Capital Partners is acting as
co-manager.
The offering is being made only by means of a prospectus. Copies
of the final prospectus relating to the offering may be obtained,
when available, from: Citigroup Global Markets Inc., c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717,
or by phone at (800) 831-9146; or Evercore Group L.L.C., Attention:
Equity Capital Markets, 55 East 52nd Street, New York, NY 10055, by
email at ecm.prospectus@evercore.com or by phone at (888)
474-0200.
A registration statement relating to these securities has been
filed with the Securities and Exchange Commission and was declared
effective on January 8, 2020. This press release shall not
constitute an offer to sell or a solicitation of an offer to buy,
nor shall there be any sale of, these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of a late-stage pipeline of novel therapies for
debilitating liver diseases. The company’s lead product candidate,
maralixibat, is an investigational oral drug in development for
progressive familial intrahepatic cholestasis (PFIC) and Alagille
syndrome (ALGS).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200108005918/en/
Media Contact: Heidi Chokeir, Ph.D. Canale Communications
619-203-5391 heidi@canalecomm.com
Investor Contact: Ian Clements, Ph.D. 650-667-4085
ir@mirumpharma.com
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Apr 2024 to May 2024
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From May 2023 to May 2024